Institutional and national budget impact of alternative pembrolizumab dosing in non-small cell lung cancer: a real-world pharmacoeconomic analysis

Igor Rubinić, Robert Likić, Marina Paladin, Nataša Skočibušić, Ines Mujčin, Ivana Mikolašević, Vera Vlahović-Palčevski

Open source

DOI: 10.1080/14737167.2026.2717291
Published: 2026-08-18
Container: Expert Review of Pharmacoeconomics & Outcomes Research
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14737167.2026.2717291,
  title = {Institutional and national budget impact of alternative pembrolizumab dosing in non-small cell lung cancer: a real-world pharmacoeconomic analysis},
  author = {Igor Rubinić and Robert Likić and Marina Paladin and Nataša Skočibušić and Ines Mujčin and Ivana Mikolašević and Vera Vlahović-Palčevski},
  year = {2026},
  journal = {Expert Review of Pharmacoeconomics \&amp; Outcomes Research},
  doi = {10.1080/14737167.2026.2717291},
  url = {https://doi.org/10.1080/14737167.2026.2717291}
}

RIS

TY  - JOUR
TI  - Institutional and national budget impact of alternative pembrolizumab dosing in non-small cell lung cancer: a real-world pharmacoeconomic analysis
AU  - Igor Rubinić
AU  - Robert Likić
AU  - Marina Paladin
AU  - Nataša Skočibušić
AU  - Ines Mujčin
AU  - Ivana Mikolašević
AU  - Vera Vlahović-Palčevski
PY  - 2026
JO  - Expert Review of Pharmacoeconomics &amp; Outcomes Research
DO  - 10.1080/14737167.2026.2717291
UR  - https://doi.org/10.1080/14737167.2026.2717291
ER  -

APA

Rubinić, I., Likić, R., Paladin, M., Skočibušić, N., Mujčin, I., Mikolašević, I., & Vlahović-Palčevski, V. (2026). Institutional and national budget impact of alternative pembrolizumab dosing in non-small cell lung cancer: a real-world pharmacoeconomic analysis. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2717291

Source records

crossref · retrieved 2026-09-26T06:57:28.062Z